ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

[1]  R. Collins,et al.  Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial , 2012, Drugs.

[2]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[3]  P. Levy.  Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus. , 2010, Metabolic syndrome and related disorders.

[4]  Ž. Reiner,et al.  Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. , 2010, Atherosclerosis.

[5]  A. Cass.  Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[6]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[7]  Lawrence Joseph,et al.  The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. , 2010, Journal of the American College of Cardiology.

[8]  Ralph D'Agostino,et al.  Cardiovascular Risk-Estimation Systems in Primary Prevention: Do They Differ? Do They Make a Difference? Can We See the Future? , 2010, Circulation.

[9]  A. Keech,et al.  Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes , 2010, Diabetologia.

[10]  Pierre Amarenco,et al.  Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. , 2010, Atherosclerosis.

[11]  P. Giral,et al.  Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. , 2010, Pharmacology & therapeutics.

[12]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[13]  R. Arora,et al.  Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. , 2010, International journal of cardiology.

[14]  Carol Coupland,et al.  Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database , 2010, BMJ : British Medical Journal.

[15]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[16]  Vivian A Fonseca,et al.  Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence , 2010, Diabetes, obesity & metabolism.

[17]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[18]  O. Melander,et al.  Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. , 2010, Journal of the American College of Cardiology.

[19]  D. Gaudet,et al.  Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[20]  P. Ladenson,et al.  Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. , 2010, The New England journal of medicine.

[21]  Ž. Reiner.  Combined therapy in the treatment of dyslipidemia , 2010, Fundamental & Clinical Pharmacology.

[22]  M. Chiariello,et al.  Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. , 2010, International journal of cardiology.

[23]  W. Borden.  Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients , 2010, Current atherosclerosis reports.

[24]  S. Humphries,et al.  Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients , 2010, Annals of clinical biochemistry.

[25]  D. Symmons,et al.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis , 2009, Annals of the rheumatic diseases.

[26]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[27]  P. Hardt,et al.  Severe hypertriglyceridemia and pancreatitis: presentation and management , 2009, Current opinion in lipidology.

[28]  B. G. Brown,et al.  Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed For , 2009, The American journal of cardiology.

[29]  M. Robson,et al.  Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. , 2009, Journal of the American College of Cardiology.

[30]  Frits R Rosendaal,et al.  Cardiovascular and noncardiovascular mortality among patients starting dialysis. , 2009, JAMA.

[31]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[32]  P. Whincup,et al.  HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. , 2009, Atherosclerosis.

[33]  I. Graham,et al.  Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. , 2009, Journal of the American College of Cardiology.

[34]  V. Pasceri,et al.  Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. , 2009, Journal of the American College of Cardiology.

[35]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[36]  J Shepherd,et al.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[37]  Ian Graham,et al.  How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[38]  A. Keech,et al.  Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate , 2009, Arteriosclerosis, Thrombosis and Vascular Biology.

[39]  D. Mozaffarian,et al.  Health effects of trans-fatty acids: experimental and observational evidence , 2009, European Journal of Clinical Nutrition.

[40]  P. Amarenco,et al.  Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention , 2009, The Lancet Neurology.

[41]  J. Ordovás.  Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention. , 2009, The American journal of clinical nutrition.

[42]  Wei Zhang,et al.  Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. , 2009, The Journal of clinical investigation.

[43]  Børge G Nordestgaard,et al.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[44]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[45]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[46]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[47]  J. Fildes,et al.  The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin , 2009, Transplantation.

[48]  G. Hitman,et al.  Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). , 2009, Clinical chemistry.

[49]  James W. Anderson,et al.  Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: Focus on dietary proteins. , 2009, Atherosclerosis.

[50]  D. Mozaffarian,et al.  Omega-6 Fatty Acids and Risk for Cardiovascular Disease: A Science Advisory From the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention , 2009, Circulation.

[51]  J. Kastelein,et al.  Combination statin–fibrate therapy: safety aspects , 2009, Diabetes, obesity & metabolism.

[52]  Jennifer G. Robinson,et al.  Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. , 2009, Journal of the American College of Cardiology.

[53]  C. N. Bairey Merz,et al.  Contraceptive hormone use and cardiovascular disease. , 2009, Journal of the American College of Cardiology.

[54]  O. Obeid,et al.  Fish Oil and the Management of Hypertriglyceridemia , 2009, Nutrition and health.

[55]  A. Keech,et al.  Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.

[56]  B. Tom,et al.  Cardiovascular morbidity in psoriatic arthritis , 2008, Annals of the rheumatic diseases.

[57]  N. Toma.  Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis , 2009 .

[58]  David W. Johnson,et al.  HMG CoA reductase inhibitors (statins) for kidney transplant recipients. , 2009, The Cochrane database of systematic reviews.

[59]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[60]  A. Catapano.  Perspectives on low-density lipoprotein cholesterol goal achievement. , 2009, Current medical research and opinion.

[61]  Michael Weis,et al.  Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.

[62]  Edward J. Mills,et al.  Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. , 2008, Journal of the American College of Cardiology.

[63]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[64]  Nikolaus Marx,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.

[65]  B. Nordestgaard,et al.  Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction , 2008, Circulation.

[66]  D. Waters,et al.  Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  S. Humphries,et al.  Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study , 2008, European heart journal.

[68]  M. Wallander,et al.  The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care , 2008, Pharmacoepidemiology and drug safety.

[69]  T. Rideout,et al.  Guar gum and similar soluble fibers in the regulation of cholesterol metabolism: Current understandings and future research priorities , 2008, Vascular health and risk management.

[70]  Y. Matsuzawa,et al.  Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). , 2008, Atherosclerosis.

[71]  S. Humphries,et al.  Familial hypercholesterolaemia: summary of NICE guidance , 2008, BMJ : British Medical Journal.

[72]  P. Jones,et al.  Plant sterols/stanols as cholesterol lowering agents: A meta-analysis of randomized controlled trials , 2008, Food & nutrition research.

[73]  B. Albertson,et al.  Lowering LDL cholesterol in adults: a prospective, community-based practice initiative. , 2008, The American journal of medicine.

[74]  Martin Adiels,et al.  Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[75]  D. Capuzzi,et al.  Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.

[76]  O. Faergeman,et al.  Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial , 2008, The Lancet.

[77]  J. Tomassini,et al.  Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. , 2008, Journal of the American College of Cardiology.

[78]  V. Kamanna,et al.  Mechanism of action of niacin. , 2008, The American journal of cardiology.

[79]  B. G. Brown,et al.  Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. , 2008, The American journal of cardiology.

[80]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[81]  L. Appel,et al.  Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease (OmniHeart): options for a heart-healthy diet. , 2008, Journal of the American Dietetic Association.

[82]  J. Lundgren,et al.  European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV * , 2008, HIV medicine.

[83]  C. la Vecchia,et al.  Non-pharmacological control of plasma cholesterol levels. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[84]  O. Faergeman,et al.  Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL) , 2008, Annals of medicine.

[85]  L. Tavazzi,et al.  ect of n-3 polyunsaturated fatty acids in patients with chronic heart failure ( the GISSI-HF trial ) : a randomised , double-blind , placebo-controlled trial , 1980 .

[86]  S. Allender,et al.  European cardiovascular disease statistics , 2008 .

[87]  R. Karas,et al.  Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. , 2008, The American journal of cardiology.

[88]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[89]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[90]  J. Price,et al.  Lipid-lowering for peripheral arterial disease of the lower limb. , 2007, The Cochrane database of systematic reviews.

[91]  P. Reiss,et al.  Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients , 2007, Antiviral therapy.

[92]  R. Califf,et al.  Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). , 2007, The American journal of cardiology.

[93]  S. Humphries,et al.  The use of Meta‐Analysis Risk Estimates for Candidate Genes in Combination to Predict Coronary Heart Disease Risk , 2007, Annals of human genetics.

[94]  Christopher P Cannon,et al.  Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.

[95]  G. Hamilton,et al.  Statins: an essential component in the management of carotid artery disease. , 2007, Journal of vascular surgery.

[96]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[97]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[98]  J. Mckenney,et al.  Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). , 2007, Atherosclerosis.

[99]  Moyses Szklo,et al.  LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). , 2007, Atherosclerosis.

[100]  S. Grundy,et al.  Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. , 2007, American heart journal.

[101]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[102]  J. Mckenney,et al.  Safety considerations with fibrate therapy. , 2007, The American journal of cardiology.

[103]  H. Bays,et al.  Safety considerations with niacin therapy. , 2007, The American journal of cardiology.

[104]  E. Duffield,et al.  Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). , 2007, The American journal of cardiology.

[105]  Paul Schoenhagen,et al.  Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. , 2007, JAMA.

[106]  D. Waters,et al.  Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study , 2007, Circulation.

[107]  Richard E Gregg,et al.  Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[108]  D. Alter,et al.  Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.

[109]  E. Rimm,et al.  Alcohol Consumption and Risk for Coronary Heart Disease among Men with Hypertension , 2007, Annals of Internal Medicine.

[110]  B. Astor,et al.  ORIGINAL INVESTIGATIONS Pathogenesis and Treatment of Kidney Disease The Impact of Reclassifying Moderate CKD as a Coronary Heart Disease Risk Equivalent on the Number of US Adults Recommended Lipid-Lowering Treatment , 2007 .

[111]  J. Lau,et al.  Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. , 2006, Atherosclerosis.

[112]  C. Del Mar,et al.  Exercise for overweight or obesity. , 2006, The Cochrane database of systematic reviews.

[113]  G. Hamilton,et al.  Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? , 2006, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[114]  R. Weber,et al.  Prevalence of risk factors for cardiovascular disease in HIV‐infected patients over time: the Swiss HIV Cohort Study , 2006, HIV medicine.

[115]  C. Packard.  Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease , 2006, Current opinion in lipidology.

[116]  P. Hepburn,et al.  Safety evaluation of phytosterol-esters. Part 9: Results of a European post-launch monitoring programme. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[117]  P. O'Malley,et al.  Meta-Analysis: The Effect of Statins on Albuminuria , 2006, Annals of Internal Medicine.

[118]  M. Tonelli,et al.  Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.

[119]  M. Sabatine,et al.  Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. , 2006, Journal of the American College of Cardiology.

[120]  Ralf Degenhardt,et al.  Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. , 2006, JAMA.

[121]  C. Rochester,et al.  LOW-FAT DIETARY PATTERN AND RISK OF CARDIOVASCULAR DISEASE-THE WOMEN'S HEALTH INITIATIVE RANDOMIZED CONTROLLED DIETARY MODIFICATION TRIAL , 2006 .

[122]  J. Mckenney,et al.  Statin safety: an assessment using an administrative claims database. , 2006, The American journal of cardiology.

[123]  J. Mckenney,et al.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. , 2006, The American journal of cardiology.

[124]  Julian P T Higgins,et al.  Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review , 2006, BMJ : British Medical Journal.

[125]  C. Hollenbeck,et al.  Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. , 2006, The Journal of clinical endocrinology and metabolism.

[126]  Matthias Briel,et al.  Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[127]  J. Manson,et al.  Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. , 2006, JAMA.

[128]  N. Wong,et al.  The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels. , 2006, Endocrine reviews.

[129]  M. Pfeffer,et al.  Effect of pravastatin in people with diabetes and chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[130]  Ž. Reiner,et al.  Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. , 2005, The American journal of cardiology.

[131]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[132]  G. Miller,et al.  Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. , 2005, Circulation.

[133]  C. Furberg,et al.  Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). , 2005, The American journal of cardiology.

[134]  M. Davidson,et al.  Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. , 2005, The American journal of cardiology.

[135]  Ž. Reiner,et al.  Effects of Rice Policosanol on Serum Lipoproteins, Homocysteine, Fibrinogen and C-Reactive Protein in Hypercholesterolaemic Patients , 2005, Clinical drug investigation.

[136]  B. Caramelli,et al.  Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. , 2005, Journal of vascular surgery.

[137]  P. Touboul,et al.  Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis , 2004, Stroke.

[138]  Sheng Kang,et al.  Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. , 2004, Atherosclerosis.

[139]  C. Summerbell,et al.  Low glycaemic index diets for coronary heart disease. , 2004, The Cochrane database of systematic reviews.

[140]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[141]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[142]  曲东锋.  Stroke Prevention by Aggressive Reduction in Cholesterol Levels , 2004 .

[143]  J. Kastelein,et al.  Advanced method for the identification of patients with inherited hypercholesterolemia. , 2004, Seminars in vascular medicine.

[144]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). , 2004, Archives des maladies du coeur et des vaisseaux.

[145]  B. Popescu,et al.  Effect of statins on the progression of bioprosthetic aortic valve degeneration. , 2003, The American journal of cardiology.

[146]  M. Koschinsky,et al.  Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. , 2003, Clinical chemistry.

[147]  P. Greenland,et al.  Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. , 2003, Archives of internal medicine.

[148]  M. Ward,et al.  Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[149]  N J Wald,et al.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[150]  A. J. Swerdlow,et al.  Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes , 2003, Diabetologia.

[151]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[152]  R. Mensink,et al.  Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. , 2003, The American journal of clinical nutrition.

[153]  Leonardo Calza,et al.  Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART , 2003, AIDS.

[154]  Walter C Willett,et al.  Optimal diets for prevention of coronary heart disease. , 2002, JAMA.

[155]  W. Kraus,et al.  Effects of the amount and intensity of exercise on plasma lipoproteins. , 2002, The New England journal of medicine.

[156]  M. Santini,et al.  Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione , 2002, Circulation.

[157]  J. Hendriks,et al.  Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families: Results of a 5-Year Follow-Up Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[158]  V. Gudnason,et al.  Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. , 2001, Journal of cardiovascular risk.

[159]  C. Ballantyne,et al.  Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S , 2001, Circulation.

[160]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[161]  J. Manson,et al.  Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. , 2001, The American journal of clinical nutrition.

[162]  B. Davis,et al.  Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.

[163]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[164]  W. Thomas,et al.  Effects of dietary fructose on plasma lipids in healthy subjects. , 2000, The American journal of clinical nutrition.

[165]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[166]  P. Shekelle,et al.  Selecting Target Conditions for Quality of Care Improvement in Vulnerable Older Adults , 2000, Journal of the American Geriatrics Society.

[167]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[168]  E. Rimm,et al.  Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors , 1999, BMJ.

[169]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[170]  J. Illnait,et al.  Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors , 1999, Clinical pharmacology and therapeutics.

[171]  B. Rosner,et al.  Cholesterol-lowering effects of dietary fiber: a meta-analysis. , 1999, The American journal of clinical nutrition.

[172]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[173]  Barry J. Davis,et al.  Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial , 1998, Annals of Internal Medicine.

[174]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[175]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[176]  O. Faergeman,et al.  The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. , 1997, Journal of cardiac failure.

[177]  G. Steinbeck,et al.  Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. , 1997, Circulation.

[178]  W. Harris,et al.  n-3 fatty acids and serum lipoproteins: human studies. , 1997, The American journal of clinical nutrition.

[179]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[180]  V. Fuster,et al.  Lipids, nutrition, and coronary heart disease. , 1996 .

[181]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[182]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[183]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[184]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, Atherosclerosis.

[185]  A. Dattilo,et al.  Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.

[186]  P. Allhoff,et al.  Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle Aged Men with Dyslipidemia , 1991 .

[187]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[188]  N. Hertzer.  Basic data concerning associated coronary disease in peripheral vascular patients. , 1987, Annals of vascular surgery.

[189]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[190]  S. Rabkin.  Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis. A control clinical trial. , 1984, Atherosclerosis.

[191]  H. Tyroler,et al.  Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial. , 1984, The American journal of cardiology.

[192]  A. Keys.  Serum cholesterol response to dietary cholesterol. , 1984, The American journal of clinical nutrition.

[193]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .